Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://www.rdinvesting.com/ and get exclusive access to our numerous stock reports and market updates.
Catalyst Pharmaceutical Partners, Inc. (NASDAQ: CPRX) shares increased 7.32 percent to close at $3.08 a share Tuesday. The stock traded between $2.90 and $3.24 on volume of 4.28 million shares traded. Analysts at Maxim Group have recently initiated coverage on the company with a "buy" rating.
Find out more about Catalyst Pharmaceutical Partners including full access to the free equity report at:
Hologic, Inc. (NASDAQ: HOLX) shares increased 2.07 percent to close at $20.49 a share Tuesday. The stock traded between $20.20 and $20.60 on volume of 5.41 million shares traded. Analysts at ISI Group have recently upgraded the company’s rating to "strong buy" from "buy". Shares of Hologic have gained approximately 2.4 percent year-to-date.
Find out more about Hologic including full access to the free equity report at:
Rovi Corporation (NASDAQ: ROVI) shares increased 1.33 percent to close at $18.35 a share Tuesday. The stock traded between $18.32 and $18.72 on volume of 1.02 million shares traded. Analysts at B. Riley & Co. have recently upgraded the company’s rating to "buy" from "neutral". Shares of Rovi have gained approximately 19.0 percent year-to-date.
Find out more about Rovi including full access to the free equity report at:
Spirit AeroSystems Holdings, Inc. (NYSE: SPR) shares increased 2.40 percent to close at $24.31 a share Tuesday. The stock traded between $23.74 and $24.45 on volume of 1.11 million shares traded. Analysts at Standpoint Research have recently upgraded the company’s rating to "buy" from "hold". Shares of Spirit AeroSystems have gained approximately 43.0 percent year-to-date.
Find out more about Spirit AeroSystems including full access to the free equity report at:
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.
Research Driven Investing
Leave a comment...